Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | ESRRG | P62508 | 10/20 | 0.64 |
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.56 |
| ▸ | RELA | Q04206 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | CASP3 | P42574 | 1/20 | 0.56 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.56 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.56 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337210 | 0.82 | ESR1 (0.64) | MAPTTP53ESRRGESR1ESR2 | |
| SCHEMBL13202371 | 0.82 | MAPT (0.59) | MAPTTP53USP2NPC1RAB9A | |
| SCHEMBL1199911 | 0.81 | NPC1 (0.63) | MAPTTP53ESRRGESR1USP2 | |
| SCHEMBL24670571 | 0.79 | KMT2A (0.59) | MAPTTP53USP2NPC1RAB9A | |
| SCHEMBL29803551 | 0.79 | KMT2A (0.59) | MAPTTP53USP2NPC1RAB9A | |
| SCHEMBL12496728 | 0.79 | RAB9A (0.67) | MAPTTP53NPC1RAB9AMEN1 | |
| SCHEMBL20746251 | 0.78 | ESRRG (1.00) | MAPTTP53ESRRGESR1ESR2 | |
| SCHEMBL20746117 | 0.77 | HPGD (0.52) | MAPTTP53ESRRGESR1ESR2 | |
| SCHEMBL2727860 | 0.77 | NPC1 (0.52) | TP53ESR1NPC1RAB9AMEN1 | |
| SCHEMBL20764078 | 0.77 | ESRRG (0.79) | MAPTTP53ESRRGESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795162-B2 | Modulators of the estrogen-related receptor | SAINT LOUIS UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795162-B2 | Modulators of the estrogen-related receptor | SAINT LOUIS UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| US-20200247792-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200247792-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2020-08-06 | — | — | US | disclosed |
| WO-2019036562-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036562-A1 | ERR INVERSE AGONISTS | SAINT LOUIS UNIVERSITY (US) | 2019-02-21 | — | — | WO | disclosed |
| US-6831068-B2 | Containing a 10,13-dioxa-15,18-diazatricyclo(10.6.2.015,20)-icos-1(18)- en-5-yl 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranoside group | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1474431-A2 | MACROLIDE ANTIBACTERIAL COMPOUNDS | Abbott Laboratories (US) | 2004-11-10 | — | — | EP | disclosed |
| US-20040009931-A1 | Macrolide antibacterial compounds | ABBVIE INC. | 2004-01-15 | — | — | US | disclosed |
| US-20030171308-A1 | Macrolide antibacterial compounds | ABBOTT LABORATORIES | 2003-09-11 | — | — | US | disclosed |
| WO-2003068790-A2 | MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247792-A1 | ERR INVERSE AGONISTS | ESRRA, ESRRB, ESR2 | MAPT 3634/4885TP53 2879/4885ESRRG 4/4885 |
| US-11795162-B2 | Modulators of the estrogen-related receptor | ESR2, GPER1, ESRRG | MAPT 4038/4885TP53 3812/4885ESRRG 3/4885 |
| US-20040009931-A1 | Macrolide antibacterial compounds | MRPL21, RPN1, CASP1 | MAPT 4610/4885TP53 4596/4885ESRRG 3406/4885 |
| US-20030171308-A1 | Macrolide antibacterial compounds | RPN1, MRPL21, CASP1 | MAPT 4628/4885TP53 4613/4885ESRRG 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.